(Total Views: 518)
Posted On: 04/12/2020 10:01:30 AM
Post# of 148878
your quote:
"NP just needs to know how much can you make per liter, how many liters can you do in a run and how long will the run take."
my quote from earlier
"When estimating production output you need to know a few things (none of which we know- correction, I was wrong before we know some things):
what is the final volume of the production bioreactor?
What is the g/L yield of the production bioreactor?"
More or less the same thing. Also I've given my estimate for the process duration before, but I don't expect you to be informed on all my posts.
Yes I do believe that NP has signed contracts without understanding fully samsung's capabilities. We have a CTO for a reason, I am sure NP does not understand a lot of the aspects of manufacturing, and he doesn't need to.
if you listen to NP he has mentioned on multiple occasion that Nitya Ray has put together this deal with Samsung
If you think NP is going to cover all aspects of manufacturing answering a question on a conference call you're mistaken
My opinion for what its worth: Current stock levels of Leronlimab are a problem, in the short term. Manufacturing output is not. I am not worried about manufacturing at all, we appear to be as well positioned as possible.
When it was brought to my attention that we make 3.5g/L I was pleasantly surprised as this is pretty high.
"NP just needs to know how much can you make per liter, how many liters can you do in a run and how long will the run take."
my quote from earlier
"When estimating production output you need to know a few things (none of which we know- correction, I was wrong before we know some things):
what is the final volume of the production bioreactor?
What is the g/L yield of the production bioreactor?"
More or less the same thing. Also I've given my estimate for the process duration before, but I don't expect you to be informed on all my posts.
Yes I do believe that NP has signed contracts without understanding fully samsung's capabilities. We have a CTO for a reason, I am sure NP does not understand a lot of the aspects of manufacturing, and he doesn't need to.
if you listen to NP he has mentioned on multiple occasion that Nitya Ray has put together this deal with Samsung
If you think NP is going to cover all aspects of manufacturing answering a question on a conference call you're mistaken
My opinion for what its worth: Current stock levels of Leronlimab are a problem, in the short term. Manufacturing output is not. I am not worried about manufacturing at all, we appear to be as well positioned as possible.
When it was brought to my attention that we make 3.5g/L I was pleasantly surprised as this is pretty high.
(1)
(1)Scroll down for more posts ▼
